肿瘤学中的循环NETosis生物标志物
本综述评估了循环中性粒细胞活化与NETosis生物标志物(如髓过氧化物酶、中性粒细胞弹性蛋白酶、瓜氨酸化组蛋白H3等)在癌症诊断、预后和监测中的价值。现有证据显示这些标志物与不良临床病理特征、生存期差、全身炎症及癌症相关血栓相关,但其预测和纵向监测证据仍为探索性,因多数研究样本小、检测异质且缺乏外部验证的临床决策阈值。
要点
- 循环NETosis标志物与癌症不良临床病理特征、生存期差及血栓相关。
- 实验室实施需关注标本基质、分析前变异、检测异质性和报告标准化。
- 当前证据多为探索性,缺乏外部验证的临床决策阈值。
核心结论
- 循环中性粒细胞活化和NETosis生物标志物在肿瘤学中具有潜在辅助价值,但向常规实验室转化需 harmonized 检测、标准化流程、前瞻性验证及增量价值证明。
研究设计与样本
- 本综述综合现有证据,评估循环中性粒细胞活化和NETosis生物标志物在癌症中的诊断、预后和监测能力,聚焦临床化学和诊断实验室医学意义。
主要发现
- 这些分析物与不良临床病理特征、生存期差、全身炎症和癌症相关血栓相关。
- 可能应用于风险分层、并发症评估、纵向疾病追踪和已建立肿瘤标志物的补充解读。
关键数值与推荐
- 实验室参数影响临床实施,包括标本基质选择、分析前变异、检测异质性、分析验证和报告标准化。
- 解释问题源于疾病特异性有限及炎症、感染和血栓疾病的混杂。
- 当前预测和纵向监测证据仍为探索性,因多数研究样本小、检测异质且缺乏外部验证的临床决策阈值。
临床怎么用
- 临床实验室应关注标本基质选择、分析前变异控制、检测方法一致性和报告标准化。
- 在解释结果时需考虑炎症、感染和血栓疾病的混杂影响。
- 目前不推荐将这些标志物用于常规临床决策,需等待前瞻性验证。
局限性
- 多数研究样本小、检测异质且缺乏外部验证的临床决策阈值。
- 疾病特异性有限,易受炎症、感染和血栓疾病混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The use of minimally invasive circulating biomarkers is becoming increasingly important in cancer management, aiding in diagnosis, risk stratification, therapeutic monitoring, and evaluation of clinically relevant complications. Neutrophil activation and extracellular trap formation are increasingly recognized biological processes in cancer-related inflammation, thrombosis, and host-tumor interactions. Circulating biomarkers of these processes, such as myeloperoxidase, neutrophil elastase, citrullinated histone H3, myeloperoxidase-DNA complexes, cell-free DNA, and nucleosome-associated markers, can be detected in blood-based samples and potentially offer clinically relevant data in oncology. This review assesses the diagnostic, prognostic, and monitoring capabilities of circulating biomarkers of neutrophil activation and NETosis in cancer, focusing on their implications for clinical chemistry and diagnostic laboratory medicine. We synthesized existing evidence showing that these analytes are associated with adverse clinicopathological features, poor survival, systemic inflammation, and cancer-related thrombosis. We also discuss their possible applications in risk stratification, complication evaluation, longitudinal disease tracking, and complementary interpretation of established tumor markers. This review identifies laboratory parameters that influence clinical implementation, such as specimen matrix selection, preanalytical variability, assay heterogeneity, analytical validation, and reporting standardization. We also addressed interpretive issues due to limited disease specificity and confounding inflammatory, infectious, and thrombotic diseases. However, current predictive and longitudinal-monitoring evidence remains exploratory because most studies are small, assay-heterogeneous, and lack externally validated clinical decision thresholds. Overall, translating neutrophil activation- and NETosis-associated biomarkers into routine diagnostic laboratory practice will involve harmonized assays, standardized workflows, prospective clinical validation, and demonstrable incremental value for the management of patients. This review presents a laboratory medicine-centered perspective for understanding the opportunities and existing constraints of these emerging adjunctive biomarkers in cancer research.
引用
- Imran M, Alzaharani AK, Alhuthali HM, et al. Circulating NETosis biomarkers in oncology. Clin Chim Acta. 2026. PMID: 42309213. doi:10.1016/j.cca.2026.121185
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。